Header Logo

Connection

Nancy Reau to Female

Back to Details
This is a "connection" page, showing publications Nancy Reau has written about Female.
Nancy Reau
Connection Strength
1.068
Female
  1. Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes. J Clin Gastroenterol. 2024 Jan 01; 58(1):91-97.
    View in: PubMed
    Score: 0.068
  2. Evaluation of Liver Disease in Pregnancy. Clin Liver Dis. 2023 02; 27(1):133-155.
    View in: PubMed
    Score: 0.062
  3. The Spectrum of Hepatic Critical Care During Pregnancy: A Clinical Review. Clin Obstet Gynecol. 2023 03 01; 66(1):176-185.
    View in: PubMed
    Score: 0.062
  4. Liver Disease During Pregnancy. Am J Gastroenterol. 2022 10 01; 117(10S):44-52.
    View in: PubMed
    Score: 0.062
  5. Potential Bias and Misconceptions in Liver Transplantation for Alcohol- and Obesity-Related Liver Disease. Am J Gastroenterol. 2021 10 01; 116(10):2089-2097.
    View in: PubMed
    Score: 0.058
  6. Had Anyone Considered the Donors? Fertility and Pregnancy Outcomes Among Female Living Donors. Liver Transpl. 2021 09; 27(9):1235-1236.
    View in: PubMed
    Score: 0.057
  7. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
    View in: PubMed
    Score: 0.055
  8. HCV in Women and Pregnancy. Hepatology. 2019 11; 70(5):1836-1840.
    View in: PubMed
    Score: 0.051
  9. Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361.
    View in: PubMed
    Score: 0.048
  10. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
    View in: PubMed
    Score: 0.047
  11. Pregnancy after liver transplantation: Can renal function quell the fear? Liver Transpl. 2018 05; 24(5):583-584.
    View in: PubMed
    Score: 0.046
  12. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
    View in: PubMed
    Score: 0.040
  13. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9.
    View in: PubMed
    Score: 0.039
  14. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196.
    View in: PubMed
    Score: 0.039
  15. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6.
    View in: PubMed
    Score: 0.033
  16. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69.
    View in: PubMed
    Score: 0.030
  17. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
    View in: PubMed
    Score: 0.028
  18. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
    View in: PubMed
    Score: 0.027
  19. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
    View in: PubMed
    Score: 0.023
  20. Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357.
    View in: PubMed
    Score: 0.015
  21. Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
    View in: PubMed
    Score: 0.014
  22. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
    View in: PubMed
    Score: 0.013
  23. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895.
    View in: PubMed
    Score: 0.013
  24. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
    View in: PubMed
    Score: 0.012
  25. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908.
    View in: PubMed
    Score: 0.012
  26. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011.
    View in: PubMed
    Score: 0.011
  27. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68.
    View in: PubMed
    Score: 0.011
  28. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218.
    View in: PubMed
    Score: 0.010
  29. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
    View in: PubMed
    Score: 0.010
  30. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
    View in: PubMed
    Score: 0.010
  31. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30.
    View in: PubMed
    Score: 0.010
  32. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
    View in: PubMed
    Score: 0.010
  33. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.009
  34. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5.
    View in: PubMed
    Score: 0.009
  35. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6.
    View in: PubMed
    Score: 0.009
  36. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
    View in: PubMed
    Score: 0.008
  37. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.